Food and Drug Administration to enable patients to import natural insulin varieties from the UK and Argentina. 2013 Insulin Dependent Diabetes Trust Mary Hunt Mary Sebastian-Hunt The diabetes community lost another member recently. I knew her as Mary Hunt, and she died at age 66.

Biosyntheticinsulin analogues have done absolutely nothing to improve my glycemic control; I'd happily trade Levemir for porcine Lente any day, and I had a comparable HbA1c back then, too, plus life was easier and cheaper. In honor of WDD and Today is DBlog Day.

Here's a news flash for investors: before investing money, try actually speaking to people who live with the disease, and if the investment involves the hormone insulin or insulin receptor ligands as they FDA calls them (meaning analogues), you had better be dam sure that you have appropriate representation for people who live with type 1 diabetes, because we constitute at least 75% of all the current insulin users according to the U.S. Insulin "Pump Evangelists".

One of the key findings was that in type 2 diabetes, beta cell destruction is caused (in part, anyway) because of some insulin molecules produced by the body being slightly deformed due to some type of disruption in the body's natural insulin production process. In other words, the body recognizes that at least some the insulin molecules are imperfect, and responds by sending out the immune system to destroy the "offending" beta cells responsible.

One of the key findings was that in type 2 diabetes, beta cell destruction is caused (in part, anyway) because of some insulin molecules produced by the body being slightly deformed due to some type of disruption in the body's natural insulin production process. In other words, the body recognizes that at least some the insulin molecules are imperfect, and responds by sending out the immune system to destroy the "offending" beta cells responsible.

Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. insulin market back in 1995 to just 43% in 2006 according to data from IMS Health. insulin market.

Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. Although Lilly's Humalog was the first insulin analog on the market, over the past decade especially, Lilly took its eyes off the ball and lost its position of dominance in the U.S. insulin market back in 1995 to just 43% in 2006 according to data from IMS Health. insulin market. MORE >>

Biosyntheticinsulin analogues have done absolutely nothing to improve my glycemic control; Id happily trade Levemir for porcine Lente any day, and I had a comparable HbA1c back then, too, plus life was easier and cheaper. But analogues have quadrupled the amount of money that I have to pay for insulin. I have Type 1 diabetes and no matter how much I exercise and how well I diet, I will be dead by tomorrow without an external supply of insulin. MORE >>

and Insulin! Not really a topic I expected to find terribly interesting reading, but the story turned out to be one of the most interesting stories which just happened to chronicle the development of synthetic "human" insulin back in the late 1970's to the early 1980's. and Dr. Quick mentioned that he had received an e-mail inquiring about the insulin which served millions of patients quite well for over 75 years. The insulin you buy from your local pharmacy in the U.S. MORE >>

and Insulin! Not really a topic I expected to find terribly interesting reading, but the story turned out to be one of the most interesting stories which just happened to chronicle the development of synthetic "human" insulin back in the late 1970's to the early 1980's. and Dr. Quick mentioned that he had received an e-mail inquiring about the insulin which served millions of patients quite well for over 75 years. The insulin you buy from your local pharmacy in the U.S. MORE >>